Inactive Instrument

GW Pharmaceuticals plc Stock Other OTC

GWPRF

GB0030544687

Biotechnology & Medical Research

Latest news about GW Pharmaceuticals plc

Jazz Pharmaceuticals : U.S. FDA approves expanded use of Jazz Pharma's sleep disorder drug Xywav	21-08-12	RE
Sector Update: Health Care Stocks Steady Premarket Tuesday	21-08-10	MT
Jazz Pharmaceuticals : GW Pharmaceuticals Bags UK Nod for New Use of Cannabis-Based Seizure Drug	21-08-10	MT
Jazz Pharmaceuticals' : Subsidiary Gets UK Approval for Epidyolex in Patients With Tuberous Sclerosis Complex-Related Seizures	21-08-10	MT
Gw Pharmaceuticals Receives Approval for Epidyolex (Cannabidiol) from the MHRA for the Treatment of Seizures Associated with Tuberous Sclerosis Complex	21-08-10	CI
Jazz Pharmaceuticals : Updates 2021 Full-Year Guidance Following GW Pharmaceuticals Buy	21-06-17	MT
Jazz Pharmaceuticals : Updates FY2021 Outlook to Reflect GW Pharmaceuticals Purchase	21-06-17	MT
Palla Pharma : Names New CEO; Shares Soar 18%	21-05-26	MT
GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from S&P Global BMI Index	21-05-10	CI
Jazz Pharmaceuticals : Completes Purchase of GW Pharmaceuticals	21-05-05	MT
GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Composite Index	21-05-04	CI
Jazz Pharmaceuticals plc completed the acquisition of GW Pharmaceuticals plc.	21-05-04	CI
GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Biotechnology Index	21-05-03	CI
Gw Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-03	CI
Jazz Pharmaceuticals : Closes $1.5 Billion Notes Offering	21-04-30	MT

More news

Analyst Recommendations on GW Pharmaceuticals plc

Fitch Affirms Jazz's IDR at 'BB-'; Outlook Positive	23-04-06	AQ
GW PHARMACEUTICALS : SVB Leerink Downgrades GW Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $220 from $200	21-02-04	MT
GW PHARMACEUTICALS : Morgan Stanley Downgrades GW Pharmaceuticals to Equal-Weight From Overweight, Adjusts Price Target to $220 From $193	21-02-04	MT
GW PHARMACEUTICALS : HC Wainwright Downgrades GW Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $220 From $162	21-02-04	MT
GW PHARMACEUTICALS : Needham Downgrades GW Pharmaceuticals to Hold from Buy	21-02-03	MT

More recommendations

Press releases GW Pharmaceuticals plc

Fitch Affirms Jazz's IDR at 'BB-'; Outlook Positive	23-04-06	AQ
Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor	23-01-23	AQ
Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing	22-03-28	AQ
JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS	22-03-02	AQ
Alkame : PAO Group, Inc.'s CBD Nutraceuticals Expected To Deliver Revenue-Generating Catalyst in 2021; New Partnerships Expand Its Long-Term CBD Pharmaceutical Programs	21-05-12	AQ

More press releases

News in other languages on GW Pharmaceuticals plc

HINTERGRUND/Bei Pharma-Übernahmen schlagen inzwischen oft Midcaps zu	21-07-06
Planète Bourse : La revue de presse du jeudi 4 févier 2021	21-02-04
Des marchés en pause sous un déluge de résultats	21-02-04
EN DIRECT DES MARCHES : Dassault Systèmes, Carrefour, Stellantis, Air France-KLM, Daimler, PayPal, Roche, Nokia...	21-02-04
MÄRKTE USA/Erholung verliert an Fahrt - Alphabet-Aktie mit Rekordhoch	21-02-03

More news

GW Pharmaceuticals Ltd is a United Kingdom-based company that operates as a biopharmaceutical company. The Company manufactures pharmaceutical products. The Company specializes in developing, processing, and manufacturing drugs in pharmaceutical preparations for human and veterinary uses. The Company serves customers worldwide.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.12%	102B
REGENERON PHARMACEUTICALS, INC.	+1.60%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.61%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.22%	13.79B
NEUROCRINE BIOSCIENCES, INC.	-0.03%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.00%	10.94B